Washington, DC - The United States supports the desire of the Venezuelan people to recover their democracy and bring the illegitimate Maduro regime to an end. Previous efforts to negotiate an end to the regime and free elections have failed because the regime has used them to divide the opposition and gain time.

Washington, DC - On May 23, the United States of America hosted the 16th U.S.-EU Information Society Dialogue (ISD) in Washington, D.C. Robert Strayer, Deputy Assistant Secretary for Cyber and International Communications and Information Policy, U.S. Department of State, and Roberto Viola, Director General for Communications Networks, Content and Technology (DG CONNECT), European Commission, co-chaired the dialogue.

Washington, DC - Friday, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer (as detected by an FDA-approved test) following progression on or after an endocrine-based regimen.

Washington, DC - Today, the United States of America and the Kingdom of the Netherlands are pleased to announce Advisor to the President Ivanka Trump and business leader Mastercard CEO Ajay Banga will lead the closing session at the Global Entrepreneurship Summit (GES) on Wednesday, June 5, 2019, in The Hague, The Netherlands.  Manisha Singh, Assistant Secretary for Economic and Business Affairs, will moderate the session.  Co-hosted by U.S. Secretary of State Michael R. Pompeo and The Netherlands Prime Minister Mark Rutte, GES 2019 is the ninth gathering of entrepreneurs, business leaders, supporters, and government officials.

Washington, DC - The U.S. Food and Drug Administration approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), the most severe form of SMA and a leading genetic cause of infant mortality.

Washington, DC - Today, the U.S. Food and Drug Administration authorized marketing of a diagnostic test to detect Zika virus immunoglobulin (IgM) antibodies in human blood. The ZIKV Detect 2.0 IgM Capture ELISA is the first Zika diagnostic test the FDA has allowed to be marketed in the U.S.; previously, tests for detecting Zika virus IgM antibodies—including the ZIKV Detect 2.0 IgM Capture ELISA—had been authorized only for emergency use under the FDA’s Emergency Use Authorization (EUA) authority.